Varenicline Treatment

Content Written By: Irwin Goldstein, MD

Persistent genital arousal disorder (PGAD), formerly known as persistent sexual arousal syndrome (PSAS), is an uncommonly reported sexual health concern associated with feelings of persistent, spontaneous, intrusive, unrelenting, and unwanted physical arousal such as throbbing, pulsating, pounding, engorgement and/or pressure/discomfort in the genital tissues, including the clitoris, labia, vagina perineum and/or anus; occurring in the absence of conscious thoughts of sexual desire or sexual interest; often associated with significant bother and distress; present throughout the person's life, consistent with primary, lifelong PGAD or developed at various ages, consistent with secondary, acquired PGAD; associated with spontaneous orgasms or feelings that orgasm is imminent or feelings that orgasmic release is needed to reduce the feelings of persistent arousal; and where symptoms are not consistently diminished by achieving orgasmic release.

Little is known about the vascular, neurologic, pharmacologic, and/or hormonal biologic-related pathophysiologies of PGAD. As it concerns central neuro-pharmacologic causes, PGAD may be secondary to Tourette’s Syndrome, epilepsy, post-blunt CNS trauma, post-neurosurgical intervention of central arteriovenous malformation, to cervical and lumbosacral surgical interventions, to use of certain antidepressants, such as the serotonin receptor antagonist trazodone, or to secondary to sudden withdrawal of selective serotonin re-uptake inhibitors (SSRIs) as occurs in sudden SSRI discontinuation syndrome.
There has been a report of varenicline tartrate used in a woman with primary lifelong PGAD who serendipitously was prescribed the drug for smoking cessation. In this woman varenicline treatment was observed to reduce unwanted arousal symptoms. She went through a cycle of starting treatment and encountering symptom relief and stopping treatment and experiencing symptom return which was repeated on several occasions.

Varenicline is a partial agonist at the α4ß2 nicotinic receptor subtype that decreases the ability of nicotine to stimulate the release of dopamine in a specific (mesolimbic) region of the brain. Central nervous system dopamine transmission is critical for the stimulation and maintenance of sexual arousal. Stimulation of dopamine receptors in certain critical areas of the brain (the hypothalamus and the limbic system) controls downward motor autonomic outflow to the genital region that can activate sexual reflexes in females. For example, treatment of women with a dopamine receptor agonist, apomorphine, has been shown to result in increased cavernosal artery peak systolic velocity values and clitoral engorgement. In the woman with primary lifelong PGAD whose symptoms of PGAD were alleviated by varenicline use, it was hypothesized that her PGAD was the result of hyperstimulated central nervous system dopamine release. It was further hypothesized that restoration of more normative sexual arousal was the result of varenicline-associated lowering of this hyperstimulated central nervous system dopamine release. Varenicline does not block dopamine release completely in response to external stimulation, and as such, varenicline treatment would be superior to the use of dopamine antagonists or selective serotonin reuptake inhibitors which would have a similar inhibitory action on dopamine release but with a high potential for untoward sexual side-effects such as anorgasmia or decreased sexual desire.

More research is needed with varenicline as a treatment for women who suffer from PGAD. Pharmacologic regulation of central nervous system monoamine neurotransmitters may represent a novel approach to management in some women who experience significant distress from PGAD and who currently have no known safe and effective pharmacologic strategies.

References:

Korda JB, Pfaus JG, Goldstein I. Persistent genital arousal disorder: a case report in a woman with lifelong PGAD where serendipitous administration of varenicline tartrate resulted in symptomatic improvement. J Sex Med. 2009 May;6(5):1479-86.

Spiller K, Xi ZX, Li X, Ashby CR Jr, Callahan PM, Tehim A, Gardner EL. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology. 2009 Jul;57(1):60-6.

Ericson M, Löf E, Stomberg R, Söderpalm B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther. 2009 Apr;329(1):225-30.

Singh J, Budhiraja S. Partial nicotinic acetylcholine (alpha4beta2) agonists as promising new medications for smoking cessation. Indian J Pharmacol. 2008 Oct;40(5):191-6.

Pfaus JG. Pathways of sexual desire. J Sex Med. 2009 Jun;6(6):1506-33.

Korda JB, Pfaus JG, Kellner CH, Goldstein I. Persistent genital arousal disorder (PGAD): case report of long-term symptomatic management with electroconvulsive therapy. J Sex Med. 2009 Oct;6(10):2901-9.

Battaglia C, Venturoli S. Persistent genital arousal disorder and trazodone. Morphometric and vascular modifications of the clitoris. A case report. J Sex Med. 2009 Oct;6(10):2896-900.

Waldinger MD, van Gils AP, Ottervanger HP, Vandenbroucke WV, Tavy DL. Persistent genital arousal disorder in 18 Dutch women: Part I. MRI, EEG, and transvaginal ultrasonography investigations. J Sex Med. 2009 Feb;6(2):474-81.

Waldinger MD, Schweitzer DH. Persistent genital arousal disorder in 18 Dutch women: Part II. A syndrome clustered with restless legs and overactive bladder. J Sex Med. 2009 Feb;6(2):482-97.

Leiblum SR, Seehuus M. FSFI scores of women with persistent genital arousal disorder compared with published scores of women with female sexual arousal disorder and healthy controls. J Sex Med. 2009 Feb;6(2):469-73.
Leiblum S, Seehuus M, Goldmeier D, Brown C. Psychological, medical, and pharmacological correlates of persistent genital arousal disorder. J Sex Med. 2007 Sep;4(5):1358-66.

Leiblum S, Seehuus M, Brown C. Persistent genital arousal: disordered or normative aspect of female sexual response? J Sex Med. 2007 May;4(3):680-7.

Waldinger MD, Venema PL, van Gils AP, Schutter EM, Schweitzer DH. Restless Genital Syndrome Before and After Clitoridectomy for Spontaneous Orgasms: A Case Report. J Sex Med. 2009 Nov 13. [Epub ahead of print]

Waldinger MD, de Lint GJ, Venema PL, van Gils AP, Schweitzer DH. Successful Transcutaneous Electrical Nerve Stimulation in Two Women with Restless Genital Syndrome: The Role of Adelta- and C-Nerve Fibers. J Sex Med. 2009 Oct 13. [Epub ahead of print]

Waldinger MD, Venema PL, van Gils AP, Schweitzer DH. New insights into restless genital syndrome: static mechanical hyperesthesia and neuropathy of the nervus dorsalis clitoridis. J Sex Med. 2009 Oct;6(10):2778-87.

Find a Doctor

Enter your city, state or zipcode and find the nearest doctor in your area who specializes in treating: Peyronie’s Disease/Curvature

diagnostic tool teaser

Share your Story

shareDo you have a personal health story that you would like to share with others? Many people, especially when newly diagnosed, find comfort in knowing that others are having a similar experience. Our story areas are a place to share experiences about living with and treating sexual health issues.

Join the Forums

joinDo you have a question, want to share medical advice, or just need to discuss your situation with someone else having a similar experience?

The forums are a resource for everyone to share and discuss their health and medical needs with others, and get answers to medical questions from the leading experts in the field of sexual medicine

Stay updated with our monthly newsletter

Sign up to receive our monthly newsletter—Get updates about advances in the field, new products and medical trials in your area. Your information will never be shared without your consent.

Leave this field empty